logo
  Join        Login             Stock Quote

Spherix (SPEX) Grants Fullife Healthcare License for D-Tagatose in Nutraceutical Products in India

 November 15, 2012 12:33 PM
 


(By Balaseshan) Spherix Inc. (NASDAQ: SPEX) said it has signed a supply and license agreement with Fullife Healthcare Pvt. Ltd. for the use of D-tagatose in nutraceutical products in India.

Under the terms of the agreement, Spherix has granted Fullife an exclusive, royalty-bearing license in India for use of Spherix's clinical data and proprietary know-how to support marketing and dosing of the D-tagatose that Spherix will also be supplying.

The D-tagatose will be used in food or cosmetic products that may provide health benefits in return for a fixed royalty on gross sales.

Spherix will provide bulk D-Tagatose to Fullife and Fullife will be responsible for all testing and development of products containing D-Tagatose for sale in India. Financial terms of the agreement were not disclosed.

[Related -Spherix (SPEX) Closes Private Placement Of Common Stock, Warrants]

According to Fullife Healthcare, D-tagatose is a versatile compound that can be formulated in many ways to help patients with metabolic syndrome and diabetes cope with their condition.

D-tagatose is a naturally occurring simple sugar that has been tested successfully as an oral treatment for glycemic control in patients with Type 2 diabetes and other indications. D-tagatose has been recognized by the U.S. Food and Drug Administration (FDA) as a GRAS (Generally Recognized as Safe) substance for use in food and beverages since 2001.

Structurally, D-tagatose is a naturally occurring stereoisomer of D-fructose, and resulted from the application of Spherix's expertise in chiral carbohydrate chemistry to create L-sugars that would retain their sweetness characteristics without being metabolized.

[Related -Solid Day Technically]

Originally developed as a reduced-calorie sugar substitute, D-tagatose is processed using the same pathways as other sugars, but at a slower rate, thus blocking the pathways and preventing the stimulation of insulin secretion and lowering blood glucose levels.

The company said D-tagatose passes to the lower intestine, where it is fermented by bacteria to produce short-chain fatty acids and carbon dioxide. It is considered a prebiotic, promoting more favorable microbial flora in the colon.

SPEX is trading down 1.85 percent at $7.95 on Thursday. The stock has been trading between $6.12 and $40.20 for the past 52 weeks.

iOnTheMarket Premium
Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article image3 US Updates Show Ongoing Growth

Three economic updates today provide more evidence that moderate growth endures for the US. The numbers du read on...

article imageBuy These Solar Stocks Before They Snapback

Sometimes the market hands you a gift. And it would be foolish not to take it. Thanks to general market read on...

article imageInvestors Are Even More Euphoric And Confident.

As noted on the blog last Thursday, even though the market had been down for three straight weeks, last read on...

article imageThe Butterfly Machine

There’s a phenomenon called the Butterfly Effect. One common quotation is “It has been said that something read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.